Peptide Reference

How Peptides Are Made

UKPWritten & reviewed by William Heath · Editor, UK Peptides research library2 min readLast reviewed 2026-08-233 cited sources

The short answer

Solid-phase peptide synthesis anchors the C-terminal residue to a resin bead and adds residues one at a time, each cycle coupling a protected amino acid then deprotecting it for the next. Because coupling is never perfectly efficient, incompleteness compounds across every cycle.

Key facts

Method
Solid-phase peptide synthesis (SPPS)
Direction
C-terminus first (opposite to ribosomes)
Support
Insoluble resin bead
Dominant chemistry
Fmoc protection
Cycle
Couple, wash, deprotect, wash
Failure mode
Deletion sequences

Why a solid support

Merrifield's insight was that anchoring the growing chain to an insoluble bead makes purification trivial between steps: excess reagents and by-products are simply washed away while the peptide stays behind. That removes the isolation step that made solution-phase synthesis impractical for anything long, and it is why the technique won a Nobel Prize and still dominates.

The cycle

Each residue takes four operations. Couple the next protected amino acid to the free amine at the chain's end. Wash away excess. Remove that residue's temporary protecting group to expose a new amine. Wash again. Repeat. A fifteen-residue peptide is fourteen of these cycles, each with its own opportunity to go incompletely.

Research material referenced

BPC-157 5mg, third-party HPLC tested

Buy BPC-157 · £16.95

Why efficiency compounds

This is the arithmetic that governs everything. At 99% coupling efficiency per cycle, a ten-residue peptide finishes at 0.99^9 ≈ 91% full-length. A thirty-residue peptide at the same efficiency reaches 0.99^29 ≈ 75%. At 98% per cycle the thirty-mer drops to about 56%. Small per-step losses become large final ones, which is why long peptides are disproportionately harder and more expensive.

Where deletion sequences come from

A chain that fails to couple in one cycle does not stop. It gets deprotected with everything else and continues in the next cycle, permanently missing one residue. The result is a peptide one residue short, chemically similar to the target and often difficult to separate from it. On a mass spectrum it appears exactly one residue's mass below the parent.

Which residues are difficult

Proline couples slowly because its secondary amine is sterically hindered, which is why BPC-157, with four prolines including a run of three, is harder to synthesise than fifteen residues suggests. Beta-branched residues such as valine and isoleucine are also slow. And non-standard residues like Aib or D-amino acids, as in ipamorelin, are more expensive and less routine.

Then purification

The crude product is cleaved from the resin and purified, almost always by reverse-phase HPLC using trifluoroacetic acid in the mobile phase. That is where the TFA counter-ion comes from, and it is why net peptide content is lower than gross powder weight.

Frequently asked questions

Why are longer peptides so much more expensive?

Coupling efficiency compounds. At 99% per cycle a ten-mer finishes around 91% full-length; a thirty-mer around 75%. Yield falls fast with length.

What is a deletion sequence?

A peptide missing one residue, produced when a coupling step fails. It continues through the remaining cycles and appears one residue's mass below the parent.

Which residues are hardest to couple?

Proline, because its secondary amine is hindered; beta-branched residues like valine and isoleucine; and non-standard residues such as Aib or D-amino acids.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Browse the wider literature

Live database searches, not fixed citations. Results change as new work is indexed.

UKP

Written and reviewed by

William Heath · Editor, UK Peptides research library

William Heath edits the UK Peptides research library. He is responsible for what is published here: every article is sourced to primary literature, every purity or identity statement traces to a signed third-party certificate for a specific lot, and corrections are made in place with the review date updated. No scientific or medical credentials are claimed on this site; the evidence is carried by the cited sources and the certificates, not by the byline.

More Peptide Reference articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.